Tags

Type your tag names separated by a space and hit enter

Baseline glucose homeostasis predicts the new onset of diabetes during statin therapy: A retrospective study in real life.

Abstract

OBJECTIVE

We evaluated the risk of altered glucose levels and new-onset diabetes (NOD) associated with statins according to glucose levels at baseline in a population treated for dyslipidemia on primary prevention for >5 years.

DESIGN

The retrospective study included 308 subjects (265 on statins and 43 controls on diet) with a follow-up of 5-15 years. The cohort was classified according to glucose tolerance at both baseline and follow-up.

RESULTS

The cumulative incidence of NOD was 13.6% (9.3% in controls and 13.5% in treated patients). NOD was diagnosed after 3.4±1.8 years. In the group with normal glucose levels at baseline, a family history of diabetes (OR: 3.4, 95% CI 1.3-8.9), BMI >30 kg/m2 (OR: 8.5, 95% CI 2.0-35.8), treatment with thiazide (OR: 21.9, 95% CI 1.2-384.2) and no alcohol consumption (OR: 0.3, 95% CI 0.1-0.8) reduced the risk of developing altered glucose levels or NOD. No effects of statins were seen. In the group with altered glucose levels at baseline, hypertension (OR: 5.0, 95% CI 1.0-25.3) and hypertriglyceridemia (OR: 3.5, 95% CI 1.0-11.8) increased the risk of remaining with altered glucose levels or developing NOD. Treatment with statins (OR: 7.5, 95% CI 1.5-37.4), in particular atorvastatin, was associated with an increased risk. In the whole population, statin therapy (OR: 4.0, 95% CI 1.1-14.1, p<0.020), and in particular simvastatin and atorvastatin, was associated with increased risk of altered glucose levels or NOD. Patients who developed or maintained altered glucose levels or NOD had a poor metabolic phenotype at baseline.

CONCLUSIONS

Statins were associated with an increased risk of NOD or altered glucose levels, mainly in subjects with altered glucose levels before the beginning of therapy. Poor metabolic phenotype and unhealthy behaviors or family history of diabetes contributed to that risk.

Links

  • FREE Publisher Full Text
  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy.

    ,

    Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy.

    ,

    Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy. Division of General Medicine, Istituto Auxologico Italiano, Ospedale S. Giuseppe, Piancavallo, VB, Italy.

    ,

    Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy.

    ,

    Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy.

    ,

    Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy.

    ,

    Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy.

    ,

    Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy.

    ,

    Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy.

    ,

    Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy.

    ,

    Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy. Division of General Medicine, Istituto Auxologico Italiano, Ospedale S. Giuseppe, Piancavallo, VB, Italy.

    ,

    Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy.

    Department of Health Sciences, University of Piemonte Orientale, Via Solaroli 17, 28100, Novara, Italy. flavia.prodam@med.uniupo.it.

    Source

    Hormones (Athens, Greece) 16:4 2017 Oct pg 396-404

    MeSH

    Adolescent
    Adult
    Aged
    Aged, 80 and over
    Atorvastatin
    Blood Glucose
    Diabetes Mellitus
    Dyslipidemias
    Female
    Follow-Up Studies
    Glucose Metabolism Disorders
    Homeostasis
    Humans
    Hydroxymethylglutaryl-CoA Reductase Inhibitors
    Male
    Middle Aged
    Retrospective Studies
    Simvastatin
    Young Adult

    Pub Type(s)

    Journal Article

    Language

    eng

    PubMed ID

    29518760

    Citation

    Ponziani, Maria Chantal, et al. "Baseline Glucose Homeostasis Predicts the New Onset of Diabetes During Statin Therapy: a Retrospective Study in Real Life." Hormones (Athens, Greece), vol. 16, no. 4, 2017, pp. 396-404.
    Ponziani MC, Karamouzis I, Mele C, et al. Baseline glucose homeostasis predicts the new onset of diabetes during statin therapy: A retrospective study in real life. Hormones (Athens). 2017;16(4):396-404.
    Ponziani, M. C., Karamouzis, I., Mele, C., Chasseur, L., Zavattaro, M., Caputo, M., ... Prodam, F. (2017). Baseline glucose homeostasis predicts the new onset of diabetes during statin therapy: A retrospective study in real life. Hormones (Athens, Greece), 16(4), pp. 396-404. doi:10.14310/horm.2002.1760.
    Ponziani MC, et al. Baseline Glucose Homeostasis Predicts the New Onset of Diabetes During Statin Therapy: a Retrospective Study in Real Life. Hormones (Athens). 2017;16(4):396-404. PubMed PMID: 29518760.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Baseline glucose homeostasis predicts the new onset of diabetes during statin therapy: A retrospective study in real life. AU - Ponziani,Maria Chantal, AU - Karamouzis,Ioannis, AU - Mele,Chiara, AU - Chasseur,Luisa, AU - Zavattaro,Marco, AU - Caputo,Marina, AU - Samà,Maria Teresa, AU - Busti,Arianna, AU - Pagano,Loredana, AU - Castello,Luigi, AU - Marzullo,Paolo, AU - Aimaretti,Gianluca, AU - Prodam,Flavia, PY - 2017/06/01/received PY - 2018/01/09/accepted PY - 2018/3/9/entrez PY - 2018/3/9/pubmed PY - 2018/9/6/medline SP - 396 EP - 404 JF - Hormones (Athens, Greece) JO - Hormones (Athens) VL - 16 IS - 4 N2 - OBJECTIVE: We evaluated the risk of altered glucose levels and new-onset diabetes (NOD) associated with statins according to glucose levels at baseline in a population treated for dyslipidemia on primary prevention for >5 years. DESIGN: The retrospective study included 308 subjects (265 on statins and 43 controls on diet) with a follow-up of 5-15 years. The cohort was classified according to glucose tolerance at both baseline and follow-up. RESULTS: The cumulative incidence of NOD was 13.6% (9.3% in controls and 13.5% in treated patients). NOD was diagnosed after 3.4±1.8 years. In the group with normal glucose levels at baseline, a family history of diabetes (OR: 3.4, 95% CI 1.3-8.9), BMI >30 kg/m2 (OR: 8.5, 95% CI 2.0-35.8), treatment with thiazide (OR: 21.9, 95% CI 1.2-384.2) and no alcohol consumption (OR: 0.3, 95% CI 0.1-0.8) reduced the risk of developing altered glucose levels or NOD. No effects of statins were seen. In the group with altered glucose levels at baseline, hypertension (OR: 5.0, 95% CI 1.0-25.3) and hypertriglyceridemia (OR: 3.5, 95% CI 1.0-11.8) increased the risk of remaining with altered glucose levels or developing NOD. Treatment with statins (OR: 7.5, 95% CI 1.5-37.4), in particular atorvastatin, was associated with an increased risk. In the whole population, statin therapy (OR: 4.0, 95% CI 1.1-14.1, p<0.020), and in particular simvastatin and atorvastatin, was associated with increased risk of altered glucose levels or NOD. Patients who developed or maintained altered glucose levels or NOD had a poor metabolic phenotype at baseline. CONCLUSIONS: Statins were associated with an increased risk of NOD or altered glucose levels, mainly in subjects with altered glucose levels before the beginning of therapy. Poor metabolic phenotype and unhealthy behaviors or family history of diabetes contributed to that risk. SN - 2520-8721 UR - https://www.unboundmedicine.com/medline/citation/29518760/Baseline_glucose_homeostasis_predicts_the_new_onset_of_diabetes_during_statin_therapy:_A_retrospective_study_in_real_life_ L2 - http://hormones.gr/preview.php?c_id=8716 DB - PRIME DP - Unbound Medicine ER -